美國 BioTrove  www.biotrove.com
基因組分析用儀器和耗材生產(chǎn)與營(yíng)銷商BioTrove Inc.向證交會(huì)申請(qǐng)首次公開發(fā)行價(jià)值7500萬美元的股票，由Piper Jaffray和Lazard Capital Markets擔(dān)任承銷商。這家總部位于馬薩諸塞州Woburn的公司計(jì)劃將其股票以“BTRV”為交易代碼在納斯達(dá)克上市。該公司2007財(cái)年虧損1900萬美元，營(yíng)收470萬美元，2006財(cái)年虧損1250萬美元，營(yíng)收270萬美元
2009-11-10，Life Technologies公司宣布收購基因組學(xué)技術(shù)公司Biotrove

BioTrove, Inc. advances life science and drug discovery research through two revolutionary micro- and nano-scale technologies. A privately held Company, BioTrove is backed by leading venture capitalist firms Catalyst Health and Technology Partners, CB Health Ventures, Vox Equity Partners I & II, Echelon Ventures and Fletcher Spaght, Inc.
BioTrove's innovative platform technologies dramatically increase throughput for pharmaceutical screening and genomics research, accelerating drug-discovery decisions and pipeline development.
OpenArray™ technology enables researchers to perform more than 3,000 assays simultaneously, generating single nucleotide polymorphism (SNP) or Real Time quantitative polymerase chain reaction (qPCR) data in the hundreds of thousands of data points per day. Large-scale studies require the examination of hundreds of loci for hundreds or thousands of nucleic acid samples. 
RapidFire™ Mass Spectrometry (RF-MS) uses an innovative microfluidic technology to facilitate sample analysis at faster than 10 seconds per sample - 10 to 100 times faster than conventional technologies. The speed of RapidFire™ technology makes MS-based screening economically viable by overcoming the throughput bottleneck.